Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.50 |
| ▸ | ATAD2 | Q6PL18 | 18/20 | 0.50 |
| ▸ | BRD2 | P25440 | 2/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.50 |
| ▸ | TAF1 | P21675 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135621 | 0.91 | BRD4 (0.50) | BRD4ATAD2BRD2BRD3BRDT | |
| SCHEMBL20134803 | 0.91 | BRD4 (0.50) | BRD4ATAD2BRD2BRD3BRDT | |
| SCHEMBL20134805 | 0.91 | BRD4 (0.50) | BRD4ATAD2BRD2BRD3BRDT | |
| Hydrochloric Acid SCHEMBL29688363 | 0.89 | BRD4 (0.49) | BRD4ATAD2BRD2BRD3BRDT | |
| SCHEMBL27101676 | 0.84 | BRD4 (0.46) | BRD4ATAD2BRD2BRD3BRDT | |
| SCHEMBL31736992 | 0.76 | MAPK1 (0.64) | BRD4ATAD2CYP1A2MEN1CYP3A4 | |
| SCHEMBL1842397 | 0.74 | RAPGEF4 (0.46) | BRD4ATAD2CYP1A2MEN1CYP3A4 | |
| SCHEMBL20135063 | 0.74 | CHEK1 (0.33) | BRD4ATAD2BRD2BRD3BRDT | |
| SCHEMBL20134889 | 0.74 | CHEK1 (0.33) | BRD4ATAD2BRD2BRD3BRDT | |
| SCHEMBL20135148 | 0.74 | CHEK1 (0.41) | BRD4ATAD2BRD2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| WO-2022114812-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2022-06-02 | — | — | WO | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | BRD4 982/4885ATAD2 2311/4885BRD2 770/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | BRD4 1494/4885ATAD2 2574/4885BRD2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.